[HTML][HTML] Cholinesterase inhibitors as Alzheimer's therapeutics
K Sharma - Molecular medicine reports, 2019 - spandidos-publications.com
Alzheimer's disease (AD) is one of the most common forms of dementia. AD is a chronic
syndrome of the central nervous system that causes a decline in cognitive function and …
syndrome of the central nervous system that causes a decline in cognitive function and …
[HTML][HTML] Neuroprotective effects of cholinesterase inhibitors: current scenario in therapies for Alzheimer's disease and future perspectives
Alzheimer's disease (AD) is a slowly progressive neurodegenerative disease
conceptualized as a continuous process, ranging from mild cognitive impairment (MCI), to …
conceptualized as a continuous process, ranging from mild cognitive impairment (MCI), to …
[HTML][HTML] Pharmacotherapy of Alzheimer's disease: Seeking clarity in a time of uncertainty
Alzheimer's disease (AD) is recognized as a major health hazard that mostly affects people
older than 60 years. AD is one of the biggest medical, economic, and social concerns to …
older than 60 years. AD is one of the biggest medical, economic, and social concerns to …
[HTML][HTML] Perspectives for new and more efficient multifunctional ligands for Alzheimer′ s disease therapy
A Zagórska, A Jaromin - Molecules, 2020 - mdpi.com
Despite tremendous research efforts at every level, globally, there is still a lack of effective
drugs for the treatment of Alzheimer′ s disease (AD). The biochemical mechanisms of this …
drugs for the treatment of Alzheimer′ s disease (AD). The biochemical mechanisms of this …
Current pharmaceutical aspects of synthetic quinoline derivatives
Quinoline derivatives are considered broad-spectrum pharmacological compounds that
exhibit a wide range of biological activities. Integration of quinoline moiety can improve its …
exhibit a wide range of biological activities. Integration of quinoline moiety can improve its …
[HTML][HTML] Tacrine-based hybrids: past, present, and future
A Bubley, A Erofeev, P Gorelkin… - International Journal of …, 2023 - mdpi.com
Alzheimer's disease (AD) is a neurodegenerative disorder which is characterized by β-
amyloid (Aβ) aggregation, τ-hyperphosphorylation, and loss of cholinergic neurons. The …
amyloid (Aβ) aggregation, τ-hyperphosphorylation, and loss of cholinergic neurons. The …
Potential alternatives to current cholinesterase inhibitors: an in silico drug repurposing approach
Acetylcholinesterase/Butyrylcholinesterase inhibitors are considered an effective method for
treating Alzheimer's disease (AD). In this current work, we have computationally analyzed 11 …
treating Alzheimer's disease (AD). In this current work, we have computationally analyzed 11 …
[HTML][HTML] Therapeutic potential of multifunctional derivatives of cholinesterase inhibitors
M Przybyłowska, K Dzierzbicka… - Current …, 2021 - ncbi.nlm.nih.gov
The aim of this work is to review tacrine analogues from the last three years, which were not
included in the latest review work, donepezil and galantamine hybrids from 2015 and …
included in the latest review work, donepezil and galantamine hybrids from 2015 and …
Cholinesterase as a target for drug development in Alzheimer's disease
Alzheimer's disease (AD) is an enormous healthcare challenge, and 50 million people are
currently suffering from it. There are several pathophysiological mechanisms involved, but …
currently suffering from it. There are several pathophysiological mechanisms involved, but …
Synthesis, molecular docking and ADME-TOX studies of new tacrine analogs as promising for Alzheimer's disease therapy
The modification of drug delivery routes can be used as a promising strategy to improve the
therapeutic profile of various drug agents. Herein, the synthesis and molecular modeling of a …
therapeutic profile of various drug agents. Herein, the synthesis and molecular modeling of a …